Tetrahydropyrimidine Lipids for mRNA delivery

Title:

Tetrahydropyrimidine Lipids for mRNA Delivery

Tech ID: 

2025-001

Status: 

Active 

Category:

Nucleic Acid Therapeutics, Biotechnology, and Drug Delivery Technology

Executive Statement:

Innovative THP ionizable lipids enhance the efficiency, stability, and safety of mRNA delivery for advanced therapies.

Description:

Tetrahydropyrimidine (THP) ionizable lipids are engineered molecules that form lipid nanoparticles (LNPs) to protect and deliver mRNA effectively into cells, enabling various mRNA-based treatments including vaccines, gene therapies, and cancer immunotherapies.

Key Advantages:

• Superior delivery efficiency resulting in higher mRNA expression and better therapeutic outcomes
• Enhanced stability protecting mRNA until target delivery
• Biodegradability reducing potential toxicity for safer treatments
• Higher efficacy demonstrated by significantly improved performance in preclinical studies compared to leading alternatives
• Customizable structure allowing tailored solutions for diverse medical applications

Problems Solved:

• Inadequate delivery efficiency of mRNA therapeutics
• Instability and degradation of mRNA before reaching target cells
• Toxicity concerns related to lipid-based delivery vehicles
• Limited flexibility in design for specific therapeutic needs

Marketing Opportunity:

• mRNA vaccines for infectious diseases such as COVID-19 and influenza
• Gene therapy for genetic disorders through precise gene editing and protein replacement
• Cancer immunotherapy via mRNA vaccines and CAR-T cell therapies targeting cancer cells
• Regenerative medicine supporting tissue repair with growth factor mRNA delivery
• Personalized medicine enabling customized mRNA treatments tailored to individual patients

Inventors: 

• Chandrabali Bhattacharya 
• Ivan Isaac 

Intellectual Property:

• U.S. Provisional Patent 63/684,835, filed 8/19/2024
• U.S.  Patent Cooperation Treaty PCT/US2025/042520, filed 9/19/2025
• U.S.  Patent Cooperation Treaty PCT/US2025/042520, filed 8/19/2025